Médecins Sans Frontières (MSF) updated two of its technical briefs, A rapid TB test for people living with HIV and Making the switch.

Treatment Action Group, Médecins Sans Frontières and Health GAP conducted a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

Group protests at New York Stock Exchange as Johnson & Johnson releases earnings report.

Treatment Action Group, Médecins Sans Frontières and Health GAP will host a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world. 

Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.

Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.

Médecins Sans Frontières acknowledges the lower price offered to the government of South Africa for delamanid, but calls for it to be significantly lower and expanded to all countries in need.

Saving more lives with optimal treatment for drug-resistant TB.